CSL pulls avacopan from Australia

4 minute read


About 150 Australian vasculitis patients will need to finish treatment or switch therapies, while the drug's longer-term future remains uncertain.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×